Phase IIb/III trial in drug-naive adults with type 2 diabetes: once-weekly efsubaglutide alfa 1 mg and 3 mg lowered HbA1c at 24 weeks vs placebo (differences -1.26% and -1.68%; 297 in phase III). GI events were commonest, mostly mild to moderate.
RCTn = 437
Zhu et al. Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial